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Metabolic acidosis and skeletal muscle adaptation to low protein diets in
chrome uremia. To maintain nitrogen equilibrium when prescribed a
low protein diet (LPD), metabolic adaptations occur involving a reduc-
tion protein turnover, principally decreased muscle protein degrada-
tion. Studies suggest that in patients with chronic renal failure (CRF)
uncomplicated by metabolic acidosis (MA), these adaptive responses
are intact. Because MA stimulates muscle proteolysis, this study
examined the hypothesis that in CRF complicated by MA, the adapta-
tion to LPD may be impaired, inducing a nitrogen wasting state. Six
adults with CRF (mean GFR: 12.8 1.5 mI/mm) and MA (mean serum
bicarbonate: 17.0 1.0 mM/liter) receiving an unrestricted diet (protein
intake: 1.2 g/kg body wt/day) were converted to an isocaloric LPD
(protein: 0.6 gfkg body wt/day). Two weeks later total urinary nitrogen
losses decreased, but skeletal muscle protein catabolism (SMPC),
assessed from the urinary 3-methyl histidine : creatinine ratio, in-
creased, demonstrating impairment in the adaptive down-regulation of
SMPC. The LPD was continued for a further two weeks and MA was
corrected with oral sodium bicarbonate (mean serum bicarbonate:
24,3 1.2 mM/liter). Correcting MA decreased SMPC to a level below
that measured prior to protein restriction. The decreased SMPC was
paralleled by further decreases in urinary nitrogen losses, confirming
that MA impaired nitrogen utilization. It is concluded that MA can
override the expected metabolic adaptive response to a LPD. The
associated impairment of nitrogen utilization not only diminishes the
efficacy of the diet, but also accelerates the loss of lean body mass.
Numerous experimental animal and human studies suggest
that chronic renal failure is a catabolic state [1—5], characterized
by diminished body fat [6] and abnormalities in protein metab-
olism leading to a progressive loss of lean body mass [7—111.
The syndrome of uremic cachexia has an adverse influence on
patient morbidity and mortality, and for these reasons optimiz-
ing patient nutritional status is particularly important [12].
Reduced protein diets have been popularized in the manage-
ment of chronic renal failure because of their efficacy in
relieving uremic symptoms and possibly protecting residual
renal function [13—16].
In the non-uremic state, restricting dietary protein promotes
compensatory responses that prevent the development of neg-
ative nitrogen balance [16, 17]. The major metabolic adaptation
to a reduction in protein intake involves a decrease in protein
turnover, achieved by a small decrease in protein synthesis and
a marked reduction in the rate of endogenous protein degrada-
tion [16, 17]. Decreased skeletal muscle proteolysis appears to
form the major component of this compensatory response [17].
Recent studies suggest that in patients with stable, moderate
renal impairment (serum creatinine 5 mg/dl), the same adaptive
responses to a LPD are operative [8]. These results, however,
may not be representative of the response to dietary protein
restriction in the presence of more advanced chronic renal
failure, which is frequently complicated by metabolic acidosis,
and has recently been identified as an important independent
stimulus for muscle proteolysis [18, 19]. Metabolic acidosis
induced by feeding non-uremic rats diets containing ammonium
chloride or hydrochloride acid stimulates skeletal muscle pro-
teolysis, thereby impairing nitrogen retention and stunting
growth [18]. Moreover, in rats with CRF and mild metabolic
acidosis, muscle protein degradation is increased but restored
to control levels after correction of the metabolic acidosis with
sodium bicarbonate [20]. These data support previous clinical
studies demonstrating that correcting metabolic acidosis im-
proves nitrogen balance in uremia and accelerates the growth of
children with renal tubular acidosis [21—24].
As the major adaptive response to a protein restricted diet
involves the downregulation of skeletal muscle proteolysis, the
potential exists for chronic metabolic acidosis to override this
response by directly stimulating skeletal muscle proteolysis.
This hypothesis is supported by our recent observation in the
rat that the usual downregulation of skeletal muscle catabolism
in the presence of a protein restricted diet is prevented by the
co-existence of metabolic acidosis, thereby accelerating nitro-
gen losses and impairing growth [25]. Such an interaction would
identify patients with chronic renal failure complicated by
metabolic acidosis as those who might be particularly suscep-
tible to accelerated endogenous protein catabolism and progres-
sive loss of lean body mass when prescribed a low protein diet.
The present study examines this hypothesis.
Methods
Patient selection
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Six adult patients (4 male, 2 female) were studied. The mean
age was 60 5.3 years (range 43 to 75 years). Each patient had
established chronic renal impairment, the primary etiology of
their renal disease was chronic interstitial nephntis [4] and
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Fig. 1. Study design.
chronic glomerulonephritis [21. All patients had chronic meta-
bolic acidosis (serum bicarbonate <21 mmollliter) documented
for at least six months prior to inclusion into the study. No
patient was taking regular medication other than phosphate
binders (aluminium hydroxide and/or calcium carbonate). Pa-
tients with a history of thyroid disorder, diabetes mellitus,
myopathy, nephrotic range proteinuria, severe anemia (hemo-
globin concentration <9.0 g/dl) hypertension requiring medica-
tion or clinical evidence of salt and water retention were
excluded from the study. The patients' weights and anthropo-
metric data had been stable for six months prior to study during
which time they received an unrestricted diet. The study
protocol was approved by the Ethical Committee of the Leices-
tershire Health Authority and written informed consent was
obtained from each participant in the study.
Study design
The study was conducted in three parts (Fig. 1). For two
weeks prior to the first study (Si), the patients continued with
their unrestricted diets. Immediately after Si, a protein re-
stricted diet (0.6 glkg body wtlday) was introduced, and the
second study (S2) was performed two weeks later. The final
study (S3) was performed after a further two weeks on the low
protein diet, during which time the patients also received oral
sodium bicarbonate tablets, I mEq/kg body wt/day in three
divided doses. Compliance with sodium bicarbonate therapy
was assessed by weekly tablet counts.
For each study, the patients were admitted to the clinical
research center at 8:30 a.m. after an overnight fast. After
resting supine for 30 minutes, venous blood samples were taken
for routine biochemical assays of electrolytes, urea, creatinine,
glucose, urate, cholesterol, triglycerides and liver function
screening using a Technicon autoanalyzer. A blood gas analysis
was performed using a fresh sample of radial arterial blood. A
urine collection was commenced 24 hours prior to admission
and analyzed for electrolytes, total protein, urate, urea and total
nitrogen (Kjeldahl method) [26]. During the 24-hour collection
period the urine was refrigerated as much as possible. A mid
stream urine specimen was examined to exclude urinary tract
infection.
Renal function was determined by measuring the clearance of
51Cr-EDTA over a four hour period after a peripheral venous
injection. The GFR was calculated from plasma measurements
of t1Cr-EDTA taken at 30 minutes, one hour, two hours and
four hours after injection. During this time, all patients main-
tained a urine output of at least 40 ml per hour. The resulting
measurement of GFR was then normalized for body surface
area. Each patient was clinically examined for evidence of salt
and water retention, and lying and standing blood pressures
were recorded at each study.
Measurement of skeletal muscle myofibrillar protein
degradation
The measurement of urinary 3-methyl histidine (3-MEH) has
been used in many studies as an index of skeletal muscle
niyofibriular protein degradation [27—3i]. 3-MEH forms an inte-
gral component of both actin and myosin within the myofibrils
of skeletal muscle. It is formed by the post-translational modi-
fication of histidine residues within the polypeptide chain.
During muscle proteolysis this amino acid is released into the
circulation, and since it cannot be re-utilized for protein syn-
thesis nor metabolized as a metabolic fuel, it is rapidly excreted
in the urine [32—341. Since more than 90% of the total body
3-MEH pool exists within the myofibrillar protein of skeletal
muscle [271, the urinary excretion of 3-MEH is proportional to
fat free body mass [35, 36] and muscle mass [37, 38] as is the
excretion of creatinine [37, 38]. Therefore, the 3-methyl
histidine : creatinine urinary excretion ratio is widely used as a
non-invasive indicator of the fractional degradation rate of
skeletal muscle protein [27—31]. Numerous precautions must,
however, be included in the protocol to validate this method.
Since under normal conditions a large proportion of 3-MEH in
the urine comes from the catabolism of dietary animal protein,
this dietary source must be eliminated when assessing endoge-
nous protein catabolism [39, 40]. To do this effectively, the diets
of the patients must be free of 3-MEH containing foods (meat,
fish and other animal protein products) for a minimum of 48
hours prior to commencing the urine collection [39]. In this
study, the diets were designed to be free of 3-MEH for 72 hours
prior to the commencement of the urine collection for each
study. A 20 ml aliquot of each 24-hour urine sample was taken
and stored frozen at —20°C. The 3-MH content in the urine
sample was determined using a Chromospek amino acid auto-
analyzer (Hilger Analytical). All samples from each phase of the
study were analyzed in the same batch to eliminate interassay
variation. The intra-assay coefficient of variation was less than
5%.
Although 3-MEH is rapidly excreted in the urine with little
tubular reabsorption relative to other amino acids, it is un-
known whether changes in the patients' urine pH could signif-
icantly modify the tubular handling of 3-MEH. To investigate
this, four patients (2 male, 2 female, mean age 61 6.2 years,
range 43 to 7i years, etiology of renal disease: 2 chronic
glomerulonephritis, 2 chronic interstitial nephritis) were in-
cluded in a separate study. The patients received a low protein
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diet for two weeks while acidotic. Three days prior to com-
mencing a urine collection for 3-MEH determination, the diet
was rendered free of 3-MEH. One day prior to the urine
collection, the patients consumed a measured quantity of lean
chicken to provide an exogenous 3-MEH load. The patients'
metabolic acidosis was then corrected with sodium bicarbonate
for two weeks and they then followed an identical protocol to
measure the excretion of the same 3-MEH load. As the exog-
enous load of 3-MEH is so great relative to basal endogenous
production rates, any measured variation in the excretion of
3-MEH per 24 hours would represent changes in tubular han-
dling of this amino acid after correcting the patients' acidosis as
the GFR did not change significantly.
Diets and nutritional assessment
The patients' dietary intake was closely monitored through-
out the study using daily diet record sheets and regular inter-
views. Prior to study 1 (Si), the patients all continued with their
unrestricted protein and calorie intakes. After Si, a low protein
diet was introduced for the next four weeks. This diet was
designed to reduce the patients' protein intake to approximately
0.6 glkg body wt/day, a recommended minimum daily require-
ment to maintain nitrogen balance in healthy adults and patients
with CRF [41—43]. In addition, the total caloric value of the low
protein diet was equiyalent to that of the previous unrestricted
diet and at least 35 kCaI/kg body wt/day, a value previously
shown to produce nitrogen equilibrium in chronic renal failure
patients consuming 0.6 g protein/kg body wt/day [41,42,44]. To
prevent a fail in dietary protein and caloric content during the
three day period when the diet was 3-MEH free, appropriate
quantities of protein and calorie supplement drinks were admin-
istered. Anthropometric data (body weight, mid arm circumfer-
ence, triceps skinfold thickness) were obtained at each study.
Statistical analysis
The results are expressed as means standard error of the
mean. A paired Student's I-test was used to compare values
obtained in the same patient. A P value of <0.05 was consid-
ered significant.
Results
All patients completed the study and dietary assessments
suggested good compliance throughout. The mean daily protein
intake while receiving the unrestricted diet during the fourteen
day period prior to Si was 82.2 2.2 g/day (1.2 g/kg body
wt/day). Following the introduction of the low protein diet
(LPD) for the fourteen day period prior to S2, the mean protein
intake decreased significantly to 38.8 1.5 g/day (0.6 g/kg body
wt/day) (Si vs. S2, P < 0.0001). For the fourteen days prior to
S3, the mean daily protein intake during this time remained
constant at 39.2 0.8 g/day (S2 vs. S3, P < 0.9). For the total
period of the LPD, individual protein intakes did not fall below
32 g/day (Table 1). Despite these changes in protein intake, the
energy content of the diets remained constant throughout, the
mean daily intake always being greater than 35 Kcal/kg body wt
(Table 1).
The mean arterial pH of patients on entry to the study
confirmed the presence of chronic metabolic acidosis (Table 1).
There was a small but insignificant improvement in the patients'
acid/base status with the LPD alone. Sodium bicarbonate
Table 1. Dietary assessment, clinical data, renal function and acid
base status in uremic patients changing from a normal to a protein
restricted diet and the effect of sodium bicarbonate supplementation
Si S2 S3
Dietary protein 82.2 2.2a 38.8 15b 39.2 0.8
intake g/day
Calorie intake Kcal/ 38.3 4.1 39.8 3.9 37.8 2.9
kg body wt/day
Body weight kg 69.4 4.7 69.1 4.9 69.4 5.1
Mid arm 28.5 i.0 28.4 1.1 28.1 1.0
circumference cm
Triceps skinfold 17.2 3.8 17.4 3.6 17.8 4.7
thickness mm
Mean arterial blood 118.2 5,7b 114 7.0 110.3 5.7
pressure mm Hg
Arterial pH 7.28 0.01" 7.31 0•02d 7.35 0.01
Urine pH 5.5 0:2c 5.8 02d 6.8 0.2
Serum bicarbonate 17.0 10" 18.3 0.6' 24.3 1.2
mmol/liter
GFR mI/mm 12.8 1.5 13.2 1.8 13.6 1.6
a p < 0.0! SI vs. S2
bP < 0.01 SI vs. S3
P < 0.05 SI vs. S3
d p < 0.01 S2 vs. S3
administration corrected the patients' metabolic acidosis (Table
1). Compliance with sodium bicarbonate therapy was good with
the weekly tablet count, indicating that there was greater than
85% consumption of the prescribed does. The therapy was well
tolerated and no adverse effects were reported. In addition,
there was no clinical evidence of salt and water retention and no
significant changes in mean arterial blood pressure. The fasting
normalized GFR remained constant throughout the study with
no significant changes either after commencing the LPD or after
correcting the metabolic acidosis (Table 1). The patients' body
weight and other anthropometric data did not change through-
out the study (Table 1).
Metabolic responses to the introduction of a low protein diet
in the presence of chronic metabolic acidosis
After two weeks receiving the LPD, there were no significant
changes in serum electrolytes, creatinine, phosphate, calcium,
urate, proteins, glucose, lipids or hematocrit (Table 2). There
were no significant changes in urine volume, sodium, chloride,
phosphate or protein excretion but urate and potassium excre-
tion fell significantly (Table 3).
The major response to the LPD was a significant change in
nitrogen metabolism. Serum urea decreased significantly (Table
2) as did urine urea excretion (Table 3). Total urinary nitrogen
excretion decreased significantly after commencing the LPD
(Si 264.4 17.9 mmol/day vs. S2 1% 17.6 mmollday, P <
0.003) (Fig. 2). This was in part due to decreased urea nitrogen
excretion (Si 108 9.7 mmolJday vs. S2 76.2 7.8 mmol/day,
P < 0.002) (Fig. 3), but also a significant fall in non-urea
nitrogenexcretion(Si 156 11.3 mmol/dayvs. S2 119.7 11.8
mmol/day, P < 0.02) (Fig. 4). The major determinant of
non-urea nitrogen in the urine is the rate of ammonia excretion
[34]. The fail in non-urea nitrogen excretion therefore most
likely represents decreased ammonia excretion, particularly as
the other more minor urinary nitrogen containing compounds
such as urate, creatinine and protein did not change sufficiently.
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Table 2. Serum biochemistry in uremic patients changing from a
normal to a protein restricted diet and the effect of sodium
bicarbonate supplementation
SI S2 S3
Urea mmol/liter 22.7 1.9k 17.6 13b 15.2 0.9
Creatinine 465.5 54.9 487.3 64.5 486.8 59
pjnol/liter
Sodium 142.7 0,9 141.8 0.7 141.2 0.3
mmol/liter
Potassium 4.8 0.1 4.8 0.1 4.9 0.2
mmol/liter
Urate 396.5 37 422.3 47.2 392.7 40,5
mmol/liter
Phosphate 1.7 0.1 1.7 O.IC 1.6 0.1
mmol/liter
Total protein 65.5 3.8 65.3 3.3 64.5 3.8
giliter
Albumin glliter 38.8 3.9 37.8 3.5 38.5 3.3
Glucose 5.1 0.3 5.0 0.3 4.8 0.1
mmol/liter
Triglycerides 2.9 0.8 3.3 1.0 3.6 1.0
mmol/liter
Cholesterol 7.4 0.6 7.6 0.9 7.7 0.6
mmol/liter
Hemoglobin 11.0 0.7 10.9 0.7 10.6 0,8
gidi
Hematocrit% 34.3 1.1 33.8 0.9 33.9 1.2
a p < 0.05 SI vs. S2
b P < 0.01 S2 vs. S3
P < 0.05 S2 vs. S3
Table 3. Urine biochemistry in uremic patients changing from a
normal to a protein restricted diet and the effect of sodium
bicarbonate supplementation
SI S2 S3
Volume liter/24 hr 1.9 0.1 1.6 0.1 1.7 0.2
Sodium mmol/24 hr 102.2 10 97.8 16d 149.2 26
Potassium mmol/24 hr 70.3 9,4a 56.3 10.2 65.8 9.3
Chloride mmol/24 hr 116.8 6.2 105.3 7.7 106.3 9.6
Phosphate mmol/24 hr 22 4.5 18.9 l.6c 15,6 1.9
Urate mmol/24 hr 2.2 0.2" 1.7 0.4 1.7 0.2
Creatinine mmol/24 hr 8.8 0.6 8.5 0.7 8.5 0.7
Urea mmol/24 hr 231.5 20,7a 163.3 16,8d 134.5 13.3
Protein 1.4 0.7 1.1 0.6 1.1 0.6
a p < 0.01 Si vs. S2
b P < 0.05 51 vs. S2
P < 0.01 S2 vs. S3d P < 0.05 S2 vs. S3
The fractional degradation rate of skeletal muscle myofibrillar
proteins was assessed from the 24-hour urinary excretion of
3-MEH and creatinine, The 3-MEH : creatinine molar ratio is a
valid measurement in this study because an exogenous source
of 3-MEH was eliminated, and therefore the urinary excretion
of this amino acid relates to its release from endogenous protein
catabolism, principally from skeletal muscle. In addition, the
GFR did not change throughout the study (Table 1), and the
renal handling of 3-MEH did not appear to be influenced by the
variations in systemic and urinary pH encountered in this
study. This latter point is illustrated by the fact that the
excretion of identical exogenous loads of 3-MEH was similar
both before and two weeks after the correction of metabolic
P< 0.02
Study 2
Fig. 2. Total urinary nitrogen excretion (mmol/24 hr) measured at each
study period.
Study 2
Fig. 3. Urine urea nitrogen excretion (mmol/24 hr) measured at each
study period.
acidosis with sodium bicarbonate therapy (before, 34.2 2.7
.tmol/mmo1 creatinine vs. after correction of acidosis, 36.1
mo1/mmo1, P < 0.8). Furthermore, the serum level and
excretion rates of creatinine were unaffected by either the diet
or change in pH (Tables 2 and 3). Therefore with all of these
criteria satisfied, any increase in the urinary 3-MEH : creatinine
ratio represents an increase in the excretion of endogenous
3-MEH.
After introducing the LPD in the presence of metabolic
acidosis, there was a highly significant increase in the
3-MEH:creatinine ratio (Si 20.33 1.0 molImmoi vs. S2
23.5 1.09 prnollmmol, P < 0.01; Fig. 5), demonstrating
increased skeletal muscle protein degradation.
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P < 0.0001
L:1
Metabolic responses to a low protein diet after correcting
chronic metabolic acidosis
After correcting metabolic acidosis, there were no significant
changes in serum electrolytes (Table 2). Urinary sodium excre-
tion increased significantly in response to sodium bicarbonate
therapy, as did potassium excretion. There were no changes in
urine volume or urine protein excretion (Table 3). There were,
however, further significant changes in nitrogen metabolism.
Serum urea and urine urea excretion both fell significantly
(Tables 2 and 3). Total nitrogen excretion also decreased further
after correcting metabolic acidosis (S2 195.9 17.6 mmollday
vs. S3 146.7 16 mmol/day, P <0.02; Fig. 2). This was in part
due to the fall in urea nitrogen excretion (S2 76.22 7.8
mmollday vs. S3 62.76 6.2mmollday, P < 0.005; Fig. 3) and to
a highly significant decrease in non-urea nitrogen excretion (S2
119.71 11.77 mmol/day vs. S3 83.96 11.53 mmollday, P <
0.0001; Fig. 4).
Correcting the patients' metabolic acidosis also had a signif-
icant impact on the rate of skeletal muscle protein degradation
(Fig. 5). Skeletal muscle protein catabolism was markedly
diminished as indicated by the significant fall in the
3-MEH creatinine molar ratio (S2 23.5 1.09 molImmol vs.
S3 18.67 1.2 mol1mmol, P < 0.01; Fig. 5). This rate of
muscle protein catabolism after correcting acidosis in the pres-
ence of a LPD was significantly less than that measured at Sl
(Sl vs. S3, P < 0.05) when the patients received an unrestricted
protein intake (Fig. 5). The significance of this decline in muscle
catabolism is underscored by the parallel decline in the urinary
nitrogen losses (Figs. 2 to 4).
Discussion
Skeletal muscle is the major organ of protein metabolism with
a large daily turnover, finely controlled by the opposing rates of
synthesis and degradation [451. This daily turnover of protein
amounts to over 300 grams per day for a 70 kg human [46, 47],
which is considerably in excess of normal dietary intake. When
P<0.01 p<0.01
I II I
L1
dietary protein intake is restricted, the major metabolic adap-
tation to preserve nitrogen equilibrium takes place in skeletal
muscle. This response is characterized by a downregulation of
protein turnover, principally due to a decrease in the rate of
muscle protein degradation [16, 17]. A maladaptive response to
protein restriction in patients with CRF could contribute to the
muscle wasting which has been frequently documented in such
patients [1—4]. Studies examining this possibility showed that in
patients with moderate renal impairment, the adaptive response
of skeletal muscle to low protein diets remains intact [8]. The
present study, however, demonstrates that these observations
are not applicable to patients with chronic renal failure compli-
cated by metabolic acidosis. In these circumstances, after
protein restriction, skeletal muscle proteolysis is augmented
rather than downregulated. The importance of metabolic acido-
sis as an independent stimulus for this protein catabolic re-
sponse is illustrated by the response to sodium bicarbonate
treatment (Fig. 5). Correcting the acidosis decreased skeletal
muscle protein catabolism to a level significantly below that
measured prior to dietary protein restriction. This supports the
hypothesis that the presence of metabolic acidosis overrides the
expected skeletal muscle metabolic adaptation to dietary pro-
tein restriction but this response can at least, in part, be
restored by correcting the acidosis. It also suggests that meta-
bolic acidosis is a significant muscle protein catabolic stimulus
in uremic patients with an unrestricted protein intake, in
keeping with our previous findings [48]. The present study also
illustrates that the patients' nitrogen losses due to increased
urea production and non-urea nitrogen excretion can be signif-
icantly decreased by correcting metabolic acidosis, and that this
response paralleled the decrease in skeletal muscle catabolism.
The facts that GFR, hematocrit and urine flow did not change
significantly throughout the study suggest that the changes in
serum urea and urea nitrogen excretion reflect changes in urea
production. The low protein diet significantly reduced urinary
nitrogen losses due to (1) decreased urea production and (2)
P < 0.02
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Fig. 4. Urine non-urea nitrogen excretion (mmol/24 hr) measured at
each study period.
Study 1 Study 2 Study 3 Study 1 Study 2 Study 3
Fig. 5. Skeletal muscle myofibrillar protein degradation (urinary
3-MEH smo1: creatinine mmol ratio per 24 hr) measured at each study
period.
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decreased non-urea nitrogen excretion. The first represents the
expected response to decreased exogenous protein catabolism
and the second is perhaps due to the increase in urine pH which
would in turn lead to a decrease in the rate of ammonia
excretion [49, 50]. Mter correcting metabolic acidosis, urinary
nitrogen losses were further significantly reduced due to further
decreases in urea production, a finding compatible with previ-
ous studies demonstrating that metabolic acidosis augments
urea production and nitrogen wasting in uremic patients and
animals, and that this response is reversible by correcting
metabolic acidosis [19—23]. Secondly, decreased ammonia ex-
cretion occurs which is the expected response to the correction
of metabolic acidosis [49, 50]. In view of the high rate of muscle
protein turnover per day, such an insidious increase in skeletal
muscle catabolism and the associated increased nitrogen losses,
persisting for an extended period of time could have a signifi-
cant deleterious effect of the preservation of lean body mass. It
is possible to approximate such a loss from our data. The
difference in nitrogen excretion before and after correction of
acidosis while receiving the low protein diet was 49.2 mmol/day
(1.18 g of nitrogen per day). As protein is approximately 16%
nitrogen, this represents 7.4 grams of protein. Skeletal muscle is
80% water by weight, therefore this loss of protein would be
equivalent to 37 g of muscle mass per day or approximately 1 kg
per month. It is emphasized that these changes occurred solely
due to changes in the patients' acid/base status and do not
reflect variation in dietary energy supply which was maintained
at a level greater than 35 Kcallday. This value was recently
defined to be adequate to maintain nitrogen equilibrium in
patients with CRF [41, 421. In addition, the level of protein
restriction utilized in this study is considered adequate to
maintain nitrogen balance in normal subjects and those with
chronic renal failure [43, 44]. Although the detrimental effects
of acidosis or the benefit of its correction were not reflected in
the anthropometric data, this is a relatively insensitive method
of measuring the small changes in body composition that would
have occurred over the short period of time of this study.
Nevertheless, previous studies have served to emphasize the
importance of chronic metabolic acidosis in stunting the growth
and acquisition of lean body mass in animals and children with
acidosis [18, 24, 511. In these and the present study, it is
noteworthy that the degree of acidosis required to significantly
affect muscle and nitrogen metabolism was not severe.
Muscle protein synthesis was not assessed in these studies,
and if it was simultaneously increased in response to acidosis
then net protein loss would not occur. This is unlikely because
previous studies have established that metabolic acidosis does
not markedly affect either the basal or insulin stimulated rate of
protein synthesis [181. Moreover, if such a compensatory
increase in protein synthesis did occur then evidence of acidosis
induced wasting and impaired nitrogen utilization would not be
apparent in the aforementioned studies. Although nitrogen
losses from other sites such as the gastrointestinal tract, skin,
hair and nails, etc., have not been quantified in this study,
losses from these sites would not change sufficiently to com-
pensate for the measured nitrogen losses. In spite of these
limitations, it is possible to approximate the patient's nitrogen
balance from our data. If it is assumed that fecal nitrogen
excretion approximates to 1 g/day and is not markedly influ-
enced by the dietary manipulations used in this study [521, then
during Sl (unrestricted diet, metabolic acidosis) total urine!
fecal nitrogen excretion can be estimated to be 53 g, during S2
(protein restriction, metabolic acidosis) 41 g, and during S3
(protein restriction, corrected metabolic acidosis) 32 g. When
expressed as a percentage of total protein intake, during Si, the
patients excreted 64% of their daily protein intake, indicating
positive nitrogen balance. During S2, the patients excreted
106% of their daily protein intake, indicating the development
of negative nitrogen balance. However, by correcting metabolic
acidosis alone, during S3, positive nitrogen balance was re-
stored (81% of protein intake excreted!24 hrs) in spite of
receiving a protein restricted diet. This suggests that sufficient
time was allowed for metabolic adaptation to the low protein
diet but the presence of metabolic acidosis prevented this
adaptation, thereby generating a state of negative nitrogen
balance. Indeed, our previous clinical study has demonstrated
that even after months of protein restricting patients with
chronic renal failure, the presence of metabolic acidosis pre-
vents complete adaptation to a low protein diet [23].
The use of 3-MEH to estimate skeletal muscle myofibrillar
protein degradation has previously received criticism because
although skeletal muscle is the largest pool of 3-MEH, higher
turnover rates in smaller pools, such as the gut, could contrib-
ute significantly to the urine excretion rate [53, 54]. Some
studies have suggested that these smaller pools may contribute
up to 40% of the daily excretion [53]. More recently, however,
the validity of these claims has been challenged [55], and
studies designed to directly measure the splanchnic release of
3-MEH in humans have demonstrated that its contribution to
urine excretion is negligible [56]. This is supported by more
recent data in humans showing that the urine excretion rate of
3-MEH is no different before and after recovery from massive
gut resection [57]. A similar observation was made in the rat
[58]. These more recent data universally conclude that 3-MEH
is a useful marker of skeletal muscle protein catabolism in
humans. In the present study the results obtained using this
method are augmented by the fact that a dietary source of
3-MEH was carefully excluded and that reducing the patients'
protein intake and/or correcting metabolic acidosis did not
significantly influence GFR or the renal tubular handling of
3-methyl histidine or creatinine. In addition, each patient acted
as his or her own control throughout the study.
Besides the capacity of metabolic acidosis to override muscle
adaptive responses to dietary protein restriction, it may also
jeopardize the two principal therapeutic objectives of the low
protein diet. The first objective of the diet is to decrease uremia.
While decreasing the protein intake did decrease urea produc-
tion in our patients, its effectiveness was significantly improved
by correcting metabolic acidosis (Fig. 3). The second objective
of the low protein diet is to protect residual renal function.
Although the mechanism of this protective effect is unknown, it
has been suggested that it relates to the capacity of the diet to
decrease intrarenal ammoniagenesis [59]. This was demon-
strated in the present study by a significant decrease in non-urea
nitrogen excretion after protein restriction (Fig. 4). The pro-
posed mechanism of nephron protection is that ammonia can
lead to amidation and therefore fixation of the complement
component C3 [60], which in turn could promote the generation
of chemotactic factors and ultimately inflammatory damage to
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the kidney [59]. This hypothesis is supported by studies dem-
onstrating that suppression of ammoniagenesis by sodium bi-
carbonate therapy both reduces the deposition of complement
and renal injury [59]. The present study demonstrates that even
in the presence of a low protein diet, metabolic acidosis
significantly augments ammonia excretion. If the protective
effect of protein results from depressed ammoniagenesis, then
its efficacy will be significantly impaired by the failure to correct
metabolic acidosis.
Clearly not all patients with chronic renal failure will tolerate
sodium bicarbonate therapy, in particular those prone to salt
and water retention and hypertension. In the present study
although there was no increase in mean arterial blood pressure
with sodium bicarbonate, the patients were pre-selected based
on the absence of pre-existing hypertension. Nevertheless,
sodium salts other than sodium chloride have been reported to
have a less pronounced effect on blood pressure [61].
In conclusion, even though the adaptive responses to the
introduction of a low protein diet in patients with mild CRF
appear to be normal [8], these diets are more frequently
prescribed for patients with more advanced renal impairment,
often complicated by metabolic acidosis. This study demon-
strates that in such patients, the metabolic adaptation to low
protein diets is impaired. Such patients should not be pre-
scribed a protein restricted diet without correction of acidosis.
If a low protein diet is prescribed in these circumstances, not
only is it likely to be less efficient in achieving its primary
objectives, it could also simultaneously expose the patient to
the risk of accelerated loss of lean body mass.
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